Pharmacogenomics is the study of how genetic variation influences responses to drugs. This includes how genetic variants affect drug metabolism, efficacy and toxicity, with the goal of improving and personalizing drug therapy.

Latest Research and Reviews

News and Comment

  • News & Views |

    The Pharmacogenomics Access & Reimbursement Symposium, a landmark event presented by the Golden Helix Foundation and the Pharmacogenomics Access & Reimbursement Coalition (PARC), was a one-day interactive meeting comprised of plenary keynotes from thought leaders across health care that focused on value-based strategies to improve patient access to personalized medicine. Stakeholders including patients, healthcare providers, industry, government agencies, payer organizations, health systems and health policy organizations convened to define opportunities to improve patient access to personalized medicine through best practices, successful reimbursement models, high-quality economic evaluations, and strategic alignment. Session topics included health technology assessment, health economics, health policy, and value-based payment models and innovation.

    • Sara L. Rogers
    • , George P. Patrinos
    •  & Benjamin G. Brown
  • Editorial |

    Given that it is based on heredity and has the ability to trace connections, genetics as a scientific discipline should be among those most attuned to diversity and global perspectives. Indigenous communities and scientists have much to contribute to genetics research, and they are making their voices heard. We celebrate these essential members of our larger genetics community, and we look forward to working together to learn from past examples, meet present challenges and support future opportunities.

    Nature Genetics 52, 135
  • News & Views |

    Despite the previous identification of genes involved in the treatment response to TNF inhibition in rheumatoid arthritis, no genetic biomarkers are currently used in clinical decision-making. Might the heterogeneous nature of the disease activity score, which is often used as the outcome measure in genetic studies, partly explain this gap?

    • Marieke J. H. Coenen
  • Comments & Opinion |

    In personalized medicine, a major aim is to provide the right treatment to the right patient. In this Comment article, Gibson discusses how a more overt and genomics-informed focus on those individuals who are unlikely to benefit from treatment could reduce prescription rates and provide financial and health-care benefits.

    • Greg Gibson